BCM
LGND icon

Bluefin Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bluefin Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-28,360
Closed -$1.2M – 747
2014
Q1 		$1.2M Buy
+28,360
New +$1.18M 0.08% 187

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Bluefin Capital Management's LGND Position: Q2 2014 in Review

Bluefin Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2014, closing a stake of 28,360 shares — an estimated $1.2M sold.

Bluefin Capital Management first reported a position in LGND in Q1 2014 and held it in 1 quarter. The position peaked at $1.2M in Q1 2014. 192 funds tracked by Wall St. Rank hold LGND as of Q2 2014.

  • Bluefin Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Bluefin Capital Management sold 28,360 Ligand Pharmaceuticals shares in Q2 2014, an estimated $1.2M.
  • Bluefin Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Bluefin Capital Management's Ligand Pharmaceuticals position peaked at $1.2M in Q1 2014.
  • 192 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2014.

Based on Bluefin Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.